NCT03527160View on ClinicalTrials.gov

Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications

CompletedOBSERVATIONAL

Enrollment

134

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

June 30, 2019

Conditions

Acute Kidney InjuryNephrotoxicity

Trial Locations (2)

35233

Children's of Alabama, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Collaborators (1)

BioPorto Diagnostics

All Listed Sponsors

collaborator

BioPorto Diagnostics

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03527160 - Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications | Biotech Hunter | Biotech Hunter